

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

09/355296
For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
(if desired) (12 characters maximum) R 1765-1 WO

Box No. I TITLE OF INVENTION

RNA POLYMERASE ASSAY

Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ASTRA AB
S-151 85 Södertälje
Sweden

☐ This person is also inventor.

Telephone No.
+46 8 553 260 00

Facsimile No.
+46 8 553 288 20

Teleprinter No.

State (that is, country) of nationality:
SE

State (that is, country) of residence:
SE

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

BALGANESH, Tanjore
Astra Biochemicals (Pvt) Ltd.
Post Box No. 8013, Sadashivnagar
Bangalore 5600 80
India

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
IN

State (that is, country) of residence:
IN

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☒ agent ☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Intellectual Property, Patents
Astra Aktiebolag
S-151 85 Södertälje
Sweden

Telephone No.
+46 8 553 260 00

Facsimile No.
+46 8 553 288 20

Teleprinter No.

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III, FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

RAMACHANDRAN, Vasanthi
Astra Biochemicals (Pvt) Ltd.
Post Box No. 8013, Sadashivnagar
Bangalore 5600 80
India

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
IN

State (that is, country) of residence:
IN

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

SHARMA, Umender
Astra Biochemicals (Pvt) Ltd.
Post Box No. 8013, Sadashivnagar
Bangalore 5600 80
India

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
IN

State (that is, country) of residence:
IN

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
☐ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
☐ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

Regional Patent

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | |
|--|--|
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> LS Lesotho |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> LT Lithuania |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> LU Luxembourg |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> LV Latvia |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> MD Republic of Moldova |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> BG Bulgaria | |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> MX Mexico |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> NO Norway |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> GD Grenada | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> GH Ghana | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> IS Iceland | |
| <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | <input checked="" type="checkbox"/> ZW Zimbabwe |
| | |
| <input checked="" type="checkbox"/> KR Republic of Korea | |
| <input checked="" type="checkbox"/> KZ Kazakhstan | |
| <input checked="" type="checkbox"/> LC Saint Lucia | <input checked="" type="checkbox"/> ZA South Africa |
| <input checked="" type="checkbox"/> LK Sri Lanka | <input checked="" type="checkbox"/> AE United Arab Emirates |
| <input checked="" type="checkbox"/> LR Liberia | <input type="checkbox"/> |

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)


Box No. VI PRIORITY CLAIM		<input type="checkbox"/> Further priority claims are indicated in the Supplemental Box.		
Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application:* regional Office	international application: receiving Office
item (1) (09.06.98) 09 June 1998	1239/MAS/98	India		
item (2) (17.07.98) 17 July 1998	9802573-7	Sweden		
item (3)				

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): (2)

* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

Box No. VII INTERNATIONAL SEARCHING AUTHORITY			
Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):	Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):		
	Date (day/month/year)	Number	Country (or regional Office)
ISA / SE	19 February 1999	ITS SE98/00791	Sweden

Box No. VIII CHECK LIST; LANGUAGE OF FILING	
This international application contains the following number of sheets: request : 4 description (excluding sequence listing part) : 19 claims : 2 abstract : 1 drawings : 8 sequence listing part of description : 3 Total number of sheets : 37	This international application is accompanied by the item(s) marked below: 1. <input checked="" type="checkbox"/> fee calculation sheet 2. <input type="checkbox"/> separate signed power of attorney 3. <input checked="" type="checkbox"/> copy of general power of attorney; reference number, if any: GF 1103/99, 4353/98 4. <input type="checkbox"/> statement explaining lack of signature 5. <input checked="" type="checkbox"/> priority document(s) identified in Box No. VI as item(s): (1) 6. <input type="checkbox"/> translation of international application into (language): 7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material 8. <input checked="" type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form 9. <input checked="" type="checkbox"/> other (specify): ITS SE98/00791
Figure of the drawings which should accompany the abstract:	Language of filing of the international application: English

Box No. IX SIGNATURE OF APPLICANT OR AGENT	
Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).	
Södertälje, 7 June 1999	
	
Ann-Sofie Sternås Intellectual Property, Patents, Astra Aktiebolag	

For receiving Office use only	
1. Date of actual receipt of the purported international application:	2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority (if two or more are competent): ISA /	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.

For International Bureau use only	
Date of receipt of the record copy by the International Bureau:	

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/569, C07K 14/35, 14/01	A1	(11) International Publication Number: WO 99/64866 (43) International Publication Date: 16 December 1999 (16.12.99)
(21) International Application Number: PCT/SE99/00979 (22) International Filing Date: 7 June 1999 (07.06.99) (30) Priority Data: 1239/MAS/98 9 June 1998 (09.06.98) IN 9802573-7 17 July 1998 (17.07.98) SE (71) Applicant (for all designated States except US): ASTRA AB [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): BALGANESH, Tanjore [IN/IN]; Astra Biochemicals (Pvt) Ltd., Sadashivnagar, P.O. Box 8013, Bangalore 560 080 (IN). RAMACHANDRAN, Vasanthi [IN/IN]; Astra Biochemicals (Pvt) Ltd., Sadashiv- nagar, P.O. Box 8013, Bangalore 560 080 (IN). SHARMA, Umender [IN/IN]; Astra Biochemicals (Pvt) Ltd., Sadashiv- nagar, P.O. Box 8013, Bangalore 560 080 (IN). (74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: A METHOD OF IDENTIFYING LIGANDS TO RNA POLYMERASE SIGMA 70 SUBUNIT		
(57) Abstract A method of identifying a ligand of a bacterial sigma ⁷⁰ subunit which comprises contacting the sigma ⁷⁰ subunit or a portion thereof comprising the anti-sigma binding region, with a test compound and a fusion protein of an anti-sigma ⁷⁰ factor of bacteriophage T ₄ , and determining whether the test compound binds competitively with the anti-sigma ⁷⁰ factor to the sigma ⁷⁰ subunit or portion thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

A METHOD OF IDENTIFYING LIGANDS TO RNA POLYMERASE SIGMA 70 SUBUNIT

TECHNICAL FIELD

5 The present invention relates to a method of identifying a ligand, in particular an inhibitor, of a bacterial RNA polymerase sigma subunit.

BACKGROUND ART

10

Sigma subunits of RNA polymerase

Transcription of genes to the corresponding RNA molecules is a complex process which is catalyzed by DNA dependent RNA polymerase, and involves many
15 different protein factors. In eubacteria, the core RNA polymerase is composed of α , β , and β' subunits in the ratio 2:1:1. To direct RNA polymerase to promoters of specific genes to be transcribed, bacteria produce a variety of proteins, known as sigma (σ) factors, which interact with RNA polymerase to form an active holoenzyme. The resulting complexes are able to recognize and attach to selected
20 nucleotide sequences in promoters.

Physical measurements have shown that the sigma subunit induces conformational transition upon binding to core RNA polymerase. Binding of the sigma subunit to the core enzyme increases the binding constant of the core
25 enzyme for DNA by several orders of magnitude (Chamberlin, M.J. (1974) Ann. Rev. Biochem. 43, 721-).

Bacterial sigma factors do not have any homology with eukaryotic transcription factors, and are consequently a potential target for antibacterial compounds.

Mutations in the sigma subunit, effecting its association and ability to confer DNA sequence specificity to the enzyme, are known to be lethal to the cell.

Characterization of sigma subunits, identified and sequenced from various organisms, allows them to be classified into three groups. The Group I sigma has also been referred to the sigma⁷⁰ class, or the "house keeping" sigma group (for a review see Lonetto et al. (1992) J. Bacteriol. 174, 3843-3849). Sigma subunits belonging to this group recognize similar promoter sequences in the cell. These properties are reflected in certain regions of the proteins which are highly conserved between species.

Another important feature of sigma-dependent transcription is that the sigma subunit dissociates from the core enzyme during elongation of mRNA. Consequently, molecules which stabilize the interaction of the sigma subunit with the core enzyme would also be capable of inactivating transcription.

Mycobacterium tuberculosis

Mycobacterium tuberculosis is a major pulmonary pathogen which is characterized by its very slow growth rate. As a pathogen it gains access to the alveolar macrophages where it multiplies within the phagosome, finally lysing the cells and being disseminated through the blood stream, not only to other areas of the lung, but also to extrapulmonary tissues.

The pathogen thus multiplies in at least two entirely different environments, involving the utilization of different nutrients and a variety of possible host factors. A successful infection would thus involve the coordinated expression of new sets of genes, transcribed by RNA polymerases associating with different sigma factors. This opens the possibility of targeting not only the sigma⁷⁰ subunits

of *M. tuberculosis*, but also other sigma subunits specific for the different stages of infection and dissemination.

The cloning and expression of *Mycobacterium tuberculosis sigA* and *sigB* genes are disclosed in the International Patent Application WO 96/38478 (Astra AB).

Anti-sigma factors

Anti-sigma (Asi) proteins are known in the art. Lysates of bacteriophage T₂ (Khesin et al. (1972) Mol. Gen. Genet 119, 299) or phage T₄ (Bogdanova et al. (1970) Mol. Biol. 4, 435; Stevens, A. (1972) Proc. Natl. Acad. Sci. U.S.A. 69, 603) have been reported to inhibit transcription of bacterial genes.

It has been established that the T₄-dependent anti-sigma⁷⁰ activity is borne by a 10 kDa protein (Stevens, A. In: RNA Polymerase p. 617-627 (Eds. R. Losick & M. Chamberlin) Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1976). A 10 kDa protein was shown to co-purify with RNA polymerase from T₄ infected *E. coli* cells and is detached together with sigma⁷⁰ from the core enzyme on phosphocellulose columns.

A gene called *asiA*, coding for the 10 kDa anti-sigma⁷⁰ factor of bacteriophage T₄, has been identified by Orsini et al. (1993) J. Bacteriol. 175, 85-93. The open reading frame encoded a 90 amino acid protein with the deduced sequence
MNKNIDTVRE IITVASILIK FSREDIVENR ANFIAFLNEI GVTHEGRKLN
QNSFRKIVSE LTQEDKKTLL DEFNEGFEGV YRYLEMYTNK (SEQ ID NO: 5). The *asiA*-encoded protein was overproduced in a phage T7 expression system and partially purified. It showed a strong inhibitory activity towards sigma⁷⁰-directed transcription by *E. coli* RNA polymerase holoenzyme. The nucleotide sequence of gene *asiA* has been deposited in the GenBank data base under accession no. M99441.

Examples of proteins regulating the sigma subunit of RNA polymerase are known also from other systems. An example is the *S. typhimurium* flagellar regulation system, which is a complex system controlled by a set of over 50 genes grouped into 13 flagellar operons. Late operon expression is positively regulated by the *fliA* gene coding for the sigma factor FliA (Suzuki et al. (1978) J. Bacteriol. 133, 904; Suzuki et al. (1981) J. Bacteriol. 145, 1036). On the other hand, the late operons are negatively regulated by the *flgM* gene. A 7.8 kDa protein has been identified as the *flgM* gene product and purified (Ohnishi et al. (1992) Mol. Microbiol. 6, 3149-3157). This FlgM protein was identified as an anti-sigma factor since it was capable to bind the FliA protein and disturbed its ability to form a complex with the RNA polymerase core enzyme.

Similarly, in *B. subtilis* gene expression, the sigma^F factor has been shown to be regulated by a 14 kDa anti-sigma factor encoded by the *spoIIAB* gene (Duncan & Losick (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 2325-2329), while the sigma^B factor is regulated by a 16 kDa anti-sigma factor encoded by the *rsbW* gene (Benson & Haldenwang (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 2330-2334).

The nucleotide sequences of the genes *flgM*, *spoIIAB* and *rsbW* are available in the GenBank data base (Accession Nos.: FLGMST.PRO for *flgM*, SPOIIAB.PRO for *spoIIAB*, M34995.PRO for *rsbW*). The sequences do not show any gross similarity with the *asiA* sequence disclosed by Orsini et al.

WO 96/25170 discloses methods for treating diseases caused by bacterial pathogens by administering the T₄ AsiA protein, which protein is shown to inhibit the RNA polymerase activity of *Bacillus subtilis* and *Mycobacterium smegmatis*.

DISCLOSURE OF THE INVENTION

In accordance with the present invention, there is provided a method of identifying a ligand of a bacterial sigma⁷⁰ subunit which comprises contacting the sigma⁷⁰ subunit or a portion thereof comprising the anti-sigma binding region, with a test compound and a fusion protein of an anti-sigma⁷⁰ factor of bacteriophage T₄, and determining whether the test compound binds competitively with the anti-sigma⁷⁰ factor to the sigma⁷⁰ subunit or portion thereof.

Preferably, the method comprises:

- (i) immobilizing the sigma⁷⁰ subunit or portion thereof on a matrix or solid support;
- (ii) adding the test compound and the fusion protein;
- (iii) adding a first antibody against the fusion protein;
- (iv) adding a labeled second antibody against the first antibody; and
- (v) determining the amount of second antibody bound to the (first antibody - fusion protein - sigma⁷⁰ subunit or portion thereof) complex formed on the matrix or solid support.

The invention provides an *in vitro* method or assay for screening peptide libraries or chemical libraries for compounds (ligands) which mimic the anti-sigma⁷⁰ factor and which thereby have the capability of inhibiting the interaction of core RNA polymerase and sigma⁷⁰ subunits. Such inhibitor compounds are potentially useful in the treatment of bacterial infections.

The capability of the identified ligands to inhibit the interaction between a bacterial core RNA polymerase and a sigma⁷⁰ subunit can be tested by known methods, in particular by a RNA polymerase assay, such as that disclosed in Orsini et al. (*supra*), wherein transcription of a DNA template, such as calf thymus DNA,

T₄ DNA or poly(dA-dT), is measured by the incorporation of a labeled RNA precursor such as [5-³H]UTP.

In the method or assay according to the invention, the sigma⁷⁰ subunit or portion thereof is preferably obtained from *Escherichia coli* (particularly the C-terminal 99 amino acids of the sigma⁷⁰ subunit containing the anti-sigma binding region) or *Salmonella typhimurium*.

In the fusion protein, the anti-sigma⁷⁰ factor of bacteriophage T₄ will preferably have an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2.

The fusion protein preferably also comprises glutathione-S-transferase (GST-Asi) or any other suitable marker gene protein product.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1: Map of plasmid vector pARC 8112.

Fig. 2: Map of plasmid vector pARC 8100.

Fig. 3: Map of plasmid vector pARC 8115.

Fig. 4: Map of plasmid vector pARC 8101.

Fig. 5: Map of plasmid vector pARC 8114.

Fig. 6: Map of plasmid vector pARC 8105.

Fig. 7: Map of plasmid vector pARC 8180.

Fig. 8: Activity of GST-Asi protein on sigma⁷⁰-dependent transcription.

Assay: 0.5 µg *E. coli* core polymerase, 2.5 µg sigma⁷⁰ protein, 1.0 µg T₄ DNA and NTPs. Varying concentrations of GST-Asi was preincubated with sigma protein before addition to the reaction mixture. ³H-UTP specific activity was 2800 - 3000 cpm/nmole.

EXAMPLES

Throughout this description the terms "standard protocols" and "standard procedures", when used in the context of molecular cloning techniques, are to be understood as protocols and procedures found in an ordinary laboratory manual such as: Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, or Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989.

EXAMPLE 1: Cloning, expression and purification of *E. coli* sigma⁷⁰

20

PCR primers corresponding to the 5'- and 3'-ends of the coding sequences of *E. coli* sigma were designed with the 5'-sequence including a site for the restriction enzyme *EcoRI* and the 3'-sequence including a site for the restriction enzyme *Sall*. The PCR amplified DNA fragment was restricted with the above mentioned restriction enzymes and cloned into the *EcoRI-Sall* sites of the expression vector pTrc99a (Amann et al. (1988) Gene 69, 301), whereafter the ligation mix was transformed into *E. coli* DH5α. Transformants harboring the recombinant plasmid with the expected restriction profile were identified.

25

E. coli DH5 α cells harboring the recombinant plasmid, labeled pARC 8112 (Fig. 1), were grown at +37°C in LB till an OD (600 nm) of 0.4 and induced with 1 mM IPTG. More than 50% of the 90 kDa sigma⁷⁰ protein was found as inclusion bodies as had been reported earlier (Borukhov & Goldfarb (1993) Protein expression and purification 4, 503). The overexpressed sigma⁷⁰ was purified and renatured following standard protocols.

The activity of the purified sigma⁷⁰ protein was confirmed by its ability to support transcription mediated by *E. coli* RNA polymerase core enzyme. *E. coli* RNA polymerase core and holoenzyme forms were purified following the protocol of Burgess and Jendriask (1975) Biochemistry 14, 4634-4638. Polymerase activity using T₄ DNA as template was assayed as described by Orsini et al. (1993) J. Bacteriol. 175, 85-93.

EXAMPLE 2: Cloning, expression and purification of *Salmonella typhimurium* sigma⁷⁰

The coding sequence of the sigma⁷⁰ of *S. typhimurium* was amplified using the forward primer shown as SEQ ID NO: 3 and the reverse primer shown as SEQ ID NO: 4. The forward primer includes the site for the restriction enzyme *EcoRI*, while the reverse primer includes the sequence encoding the stop codon and a site for the restriction enzyme *SalI*. *S. typhimurium* DNA was used as template and the amplified fragment digested with appropriate enzymes. This fragment was then ligated to *EcoRI* - *SalI* digested pTrc 99A (Amann et al. (1988) Gene 69, 301) and transformed into *E. coli* DH5 α to obtain the recombinant plasmid pARC 8118. Plasmid DNA of pARC 8118 was digested with *EcoRI* - *HindIII* and the released 2.3 kb DNA fragment encompassing the entire coding sequence of *S. typhimurium* sigma⁷⁰ was cloned into the *EcoRI* - *HindIII* digested pRSET B (Kroll et al. (1993) DNA and Cell Biol. 12, 441) vector which has not only

the T7 promoter but also sequences encoding a his tag which is now fused at the C-terminus of *S. typhimurium* sigma⁷⁰. The recombinant plasmid encoding the *S. typhimurium* sigma⁷⁰ fused to a His tag was labeled pARC 8133.

5 Plasmid DNA of pARC 8133 was then used to transform the expression host *E. coli* BL21(DE3) and transformants obtained at +37°C. Cells harboring pARC 8133 were grown in LB at +37°C till an OD of 0.4 at 600 nm and induced with 1 mM IPTG for 4 hours. The cells were pelleted, suspended in buffer and sonicated, according to standard methods. The lysed cells were clarified by centrifugation at 45,000 rpm
10 for 60 min at +4°C and the clarified supernatant was loaded directly on Ni-agarose (Pharmacia) and washed with 50 mM imidazole. The bound protein was eluted with 200 mM imidazole and dialysed overnight at +4°C against 50 mM Tris-Cl, pH 7.5. The eluate was concentrated using Amicon cone filters to 1/10 volume. The concentrated protein was cleaved with enterokinase, used at a ratio of 1:50 of
15 the enzyme, at +25°C for 14 hours. The cleaved mixture was passed through a Ni²⁺ agarose column and the unbound material collected. The cleaved protein was analyzed for homogeneity by SDS-PAGE.

20 EXAMPLE 3: Toxicity of the anti-sigma protein

3.1. Cloning of the *asiA* gene

The coding sequence for the *asiA* gene (Orsini et al., *supra*) was amplified from the
25 genomic DNA of bacteriophage T₄ by PCR using the forward primer shown as SEQ ID NO: 5 and the reverse primer designated shown as SEQ ID NO: 6.

The 5'-primer included the sequence of the restriction enzyme *NcoI* while the 3'-primer included the sequence for the restriction enzyme *BamHI*. The coding
30 sequence was amplified by PCR following standard protocols and the amplified

fragment ligated to *NcoI* - *Bam*HI restricted pBR329 and transformed into competent cells *E. coli* DH5 α . Recombinants were selected at +37°C as chloramphenicol sensitive, ampicillin resistant transformants. One of the transformants having the desired restriction pattern was labeled pARC 8100 (Fig. 2).

The inclusion of the sequence encoding *NcoI* resulted in the change of the second amino acid from asparagine to glycine (SEQ ID NO: 2). The nucleotide sequence of the *asiA* gene cloned in pARC 8100 was verified by double stranded sequencing and found to be identical to the *asiA* sequence as disclosed by Orsini et al., except for the expected change of codon for the second amino acid as a result of the PCR cloning protocol used.

3.2. *In vivo* toxicity of *asiA* product in *E. coli*

(A)

The *NcoI* - *Bam*HI DNA fragment from pARC 8100 was ligated to pET 8c Km (Umender K. Sharma et al., J. Bact., 177, 6745 (1996)) and kanamycin resistant transformants with *E. coli* DH5 α were selected at +37°C. One of the transformants harboring a plasmid with the expected restriction enzyme profile was labeled pARC 8115 (Fig. 3). pARC 8115 plasmid DNA was then used to transform the expression host *E. coli* BL21(DE3) (Studier et al., *supra*) and transformants selected both at +37°C and at +30°C. However, no viable transformants could be obtained at either of the temperatures. The leaky expression from the T7 promoter in pET 8c being much higher than from pET 11d(Km) (Studier et al., *supra*), the toxicity of the *asiA* product could explain the non-transformability.

Transformants could however be obtained using *E. coli* BL21(DE3)/pLysS as host, in which the leaky expression is additionally repressed by the T7 lysozyme expressed from pLysS.

(B)

The *Nco*I - *Bam*HI 284 bp DNA fragment was obtained from pARC 8100 and ligated to the *Nco*I - *Bam*HI sites of pET 11d Km (Umender K. Sharma et al., J. Bact., 177, 6745 (1996)) and transformed into *E. coli* DH5 α . Transformants were selected for kanamycin resistance. Plasmid preparations from individual transformants were digested with restriction enzymes and the correct transformant that released the 284 bp fragment after *Nco*I - *Bam*HI digest was labeled pARC 8101 (Fig. 4). The transformants were selected at +37°C and appeared normal.

pARC 8101 DNA was then used to transform the expression host *E. coli* BL26(DE3). BL26 is a lac Iq isogenic strain of BL21 (Studier et al., *supra*). Transformants selected for kanamycin both at +37°C and at +30°C.

The transformants obtained at +37°C were morphologically sick and non-viable indicating the acute toxicity of the leaky expression of the *asiA* gene. In contrast, healthy colonies could be obtained when transformants were selected at +30°C where the leaky expression from the T7 promoter can be expected to be negligible.

BL26(DE3)/pLysS colonies were healthy both at +37°C and +30°C, indicating that the tight regulation of expression in this strain made the *asiA* gene non-toxic to the host. Transformants obtained from DH5 α were also healthy both at +37°C and +30°C, indicating that the gene when transformed into a non-expression host was non-toxic.

(C)

The *asiA* gene was excised from pARC 8101 as a *Xba*I - *Bam*HI DNA fragment to include the sequence for the ribosome binding site and ligated to the low copy vector, *Xba*I - *Bam*HI cleaved pWKS129 (Wang & Kushner (1991) Gene 100, 195) and the ligation mix transformed to *E. coli* DH5 α . Recombinant plasmid harboring the *asiA* gene was identified by restriction profile and labeled pARC 8114 (Fig. 5).

This plasmid DNA when transformed into *E. coli* BL21(DE3) gave viable transformants both at +37°C and +30°C, since the low copy number of the plasmid reduced the level of the AsiA protein expressed through leaky expression.

EXAMPLE 4: Glutathione-S-transferase - Anti-sigma fusion protein

4.1. Cloning of fusion protein in *E. coli*

10 The coding sequence for the *asiA* gene was excised as an *NcoI* - *Bam*HI fragment from pARC 8100 and ligated to *NcoI* - *Bam*HI cleaved pARC 0499. The plasmid pARC 0499 has a *NcoI* site in frame with the glutathione-S-transferase encoding sequence, enabling fusion of the N-terminus of *asiA* sequences. The ligation mix was transformed into *E. coli* DH5α and transformants selected at +37°C and
15 +30°C. Viable colonies were obtained at both temperatures indicating the N-terminal fusion reduces the toxicity of the protein. The recombinant plasmid obtained with the sequences encoding GST-AsiA was labeled pARC 8105 (Fig. 6).

The GST-AsiA fusion protein was purified as follows: *E. coli* DH5α harboring
20 pARC 8105 was grown in LB till an OD at 600 nm of 0.6 at +37°C followed by the addition of 1 mM IPTG and allowing growth for a further period of 2 hours. The cells were then centrifuged at 5000 rpm for 10 minutes. The pelleted cells were suspended in Buffer A (phosphate buffered saline (PBS) pH 7.5, 5 µg/ml aprotinin, 5 µg/ml leupeptin) and sonicated. The sonicate was clarified at 45,000 rpm for 10
25 minutes at +4°C and the supernatant passed through a Glutathione-Sepharose 4B column previously equilibrated with PBS. The column was washed with 5 bed volumes of 1 M urea once followed by washing with PBS (10 bed volumes). The bound protein was eluted with 10 mM glutathione and the eluate dialysed overnight against buffer containing 50 mM Tris(hydroxymethyl)aminomethane

hydrochloride (Tris HCl), pH 7.5. The dialysed protein was then concentrated to 1/10 vol using Amicon cone filters. The concentrated protein was then treated with 1:50 ratio of Factor Xa protease in a buffer containing 50 mM Tris HCl, pH 7.5, 100 mM NaCl, 1 mM CaCl_2 at +25°C for 4 hours. The digested eluate was then
5 passed through a Glutathione-Sepharose column and the unbound fraction collected and analyzed for the purity of the AsiA protein by SDS-PAGE.

4.2. Cloning of fusion protein in yeast

10 The expression and purification of the GST-AsiA fusion protein in *E. coli* did not allow large scale production because of the inherent toxicity of the fusion protein. To obtain large quantities of the AsiA protein, the possibility of expressing the GST-AsiA fusion protein in a yeast host was investigated. As the *Saccharomyces* species do not have a sigma⁷⁰ homologue, the AsiA protein was expected not to
15 have toxicity effects on the transcription apparatus of the host and thus for initial experiments a *Saccharomyces cerevisiae* expression system was chosen.

The gene encoding the GST-AsiA fusion protein on the plasmid pARC 8105 was amplified using the forward primer shown as SEQ ID NO: 7 and the reverse
20 primer shown as SEQ ID NO: 8. The amplified 1.0 kb fragment was restricted with *Bgl*III and *Hind*III which are the sites introduced by the primer sequence at the 5'- and 3'-ends of the amplified PCR fragment. The *Bgl*III – *Hind*III restricted fragment was ligated into the *Bgl*III – *Hind*III restricted *Saccharomyces cerevisiae* cloning vector pSW6 (Pascall et al. (1991) J. Mol. Endocrinol. 6, 63-70). The ligation mixture
25 was transformed into the *Saccharomyces cerevisiae* host CGY1585 and transformants selected on leucine (3 µg/ml).

Individual transformants from both reaction mixtures were screened for the presence of plasmid with the expected restriction profile. The recombinant
30 plasmid obtained with the vector PSW6 was labeled pARC 8180 (Fig. 7).

S. cerevisiae CGY 1585 strain harbouring pARC 8180 were grown using standard procedures and lysed by passing the concentrated cell suspension through a French Press. The lysate was then centrifuged at 10,000 rpm and the supernatant applied to a Glutathione-Sepharose column (Pharmacia) and the fusion protein purified following standard protocols.

The purified GST-AsiA fusion protein was cleaved with Factor Xa as recommended and the AsiA protein separated. The yield of the purified AsiA protein was 500 µg/l. The activity of the GST-AsiA protein, expressed and purified from *Saccharomyces*, was compared to that obtained from *E. coli* and found to be identical in its ability to inhibit sigma⁷⁰ mediated transcription of T₄ template (Fig. 8). AsiA protein purified from GST-AsiA after Factor Xa cleavage also inhibited *E. coli* sigma⁷⁰ dependent transcription.

The ability to overexpress and purify large quantities of the AsiA protein in *Saccharomyces* without toxicity problems for the host also indicates that the AsiA protein does not have a corresponding sigma⁷⁰ homologue in this species. As the *Saccharomyces* RNA polymerase is similar to that of higher eukaryotes it also substantiates the fact that the AsiA protein is toxic only to the prokaryotic transcription apparatus.

In order to test the feasibility of expressing AsiA in alternative yeast expression systems, *Pichia pastoris* expression system was chosen. The gene encoding GST-AsiA was amplified by PCR from pARC 8105 and cloned into pPIC9K (Invitrogen).

5' primer (asi34) - TA TAC GTA TCC CCT ATA CTA GGT TAT TGG

3' primer (asi35) - T TGC GGC CGC TTA TTT GTT CGT ATA CAT

PCR conditions used were: melting temperature 94 °C

5 annealing temperature 50 °C

extension temperature 72 °C

and 30 cycles were performed.

1Kb PCR product was cloned as SnaBI-NotI fragment into pPIC9K (pARC 8274).

10 *Pichia pastoris* transformants of pARC 8274 were selected based on G 418 resistance. Expression studies indicated that GST-AsiA was secreted into the culture supernatant. GST-AsiA purified from the culture supernatant was found to inhibit *in vitro* transcription as efficiently as that of either *E. coli* or the *Saccharomyces* GST-AsiA.

15

This indicates that it is feasible to produce recombinant GST-AsiA in a yeast expression system.

20 EXAMPLE 5: *In vitro* AsiA-sigma⁷⁰ interaction assays

5.1. RNA polymerase assay

25 The *E. coli* RNA polymerase assay was standardized following the protocol of Orsini et al. (J. Bacteriol. 175, 85-93, 1993) using T₄ phage DNA as template to quantify sigma⁷⁰ dependent transcription. *E. coli* RNA polymerase core enzyme was purified following the protocol of Burgess and Jendriask (1975) Biochemistry 14, 4634-4638.

5.2. Inhibition of *E. coli* transcription by AsiA protein

Increasing concentrations of AsiA protein expressed in *S. cerevisiae* was added to the reaction mixture and the transcription mediated by the *E. coli* RNA polymerase
5 quantified. The results showed that increasing concentrations of AsiA protein completely inhibited transcription mediated by *E. coli* sigma⁷⁰.

5.3. Inhibition of *E. coli* transcription by GST-AsiA fusion protein

10 The GST-AsiA fusion protein was purified from *S. cerevisiae* as described in Section 5.2 and used at different concentrations in the *E. coli* sigma⁷⁰ mediated RNA polymerase transcription assay, using phage T₄ DNA as template. The GST-AsiA fusion protein inhibited >80% the sigma⁷⁰ mediated transcription when the core enzyme was reconstituted with 2.5 µg of sigma⁷⁰ protein.

15

5.4. Reactivation of *E. coli* sigma⁷⁰ mediated transcription

Increasing concentrations of *E. coli* sigma⁷⁰ protein were added to the reaction mixture containing 0.1 µg of AsiA. As shown in Table 1, addition of sigma⁷⁰
20 protein could reactivate transcription mediated by *E. coli* RNA polymerase. This reversal of inhibition demonstrates the specific interaction of the AsiA protein with sigma⁷⁰.

TABLE 1

	<i>E. coli</i> sigma ⁷⁰	<i>S.</i> <i>typhimurium</i> sigma ⁷⁰
	[³ H]UTP (nmol)	
<i>E. coli</i> RNA polymerase	2.1	2.3
<i>E. coli</i> RNA polymerase + 0.1 µg AsiA	0.57	0.34
<i>E. coli</i> RNA polymerase + 0.1 µg AsiA + 4 µg sigma ⁷⁰	2.3	3.0
<i>E. coli</i> RNA polymerase + 0.1 µg AsiA + 4 µg sigma ⁷⁰ (AsiA preincubated)	0.68	0.98

5.5. Effect of *Salmonella typhimurium* sigma⁷⁰ on *E. coli* transcription

5

As described in Section 5.1, the *E. coli* RNA polymerase activity assay was standardized with purified enzyme and phage T₄ DNA as template. The RNA polymerase could be >80% inhibited by 0.07 µg of purified AsiA protein.

10 To a reaction mixture containing the *E. coli* RNA polymerase, T₄ DNA and 0.1 µg of AsiA, increasing concentrations of purified *Salmonella typhimurium* sigma⁷⁰ was added and the RNA polymerase activity quantified. As shown in Table 1, addition of 4 µg of *S. typhimurium* sigma⁷⁰ could restore the activity of the RNA polymerase.

15

5.6. Preincubation of sigma⁷⁰ with AsiA

To a reaction mixture containing *E. coli* RNA polymerase and T₄ DNA template there was added 0.1 µg AsiA and 4 µg *E. coli* or *S. typhimurium* sigma⁷⁰,

preincubated at +37°C for 10 min with 0.1 µg of AsiA. As shown in Table 1, preincubation of the sigma⁷⁰ with AsiA abolished the ability of the sigma⁷⁰, from both *E. coli* and *S. typhimurium*, to activate *E. coli* RNA polymerase.

5

EXAMPLE 6: Competitive ELISA for quantification of AsiA-sigma⁷⁰ interaction.

Screening assays

10 The above principles provide a basis for a method of identification of oligonucleotide sequences encoding peptides, which may be either related or unrelated to the AsiA peptide, and which could efficiently bind to sigma⁷⁰ subunits from *E. coli*, *S. typhimurium* and/or other housekeeping or virulence-associated sigma subunits of bacterial pathogens.

15

The identification of such peptide structures would enable the further identification, by known methods, of peptoids, peptidomimetics and organic molecules which can be tested in transcription assays for inhibition of sigma⁷⁰ dependent transcription.

20

Truncated sigma⁷⁰ (C-terminal 99 amino acids) which has been shown to be the anti-sigma binding region of sigma⁷⁰ of *E. coli* (Severinova et al., J. Mol. Biol. (1996) 263 (5), pp 637-647) was cloned and expressed in a His tag expression vector resulting in a (His)₅-tagged protein product.

25

A solution of the protein product (200 pmoles/ml) in a pH 7.5 buffer comprising Tris HCl (10 mM) and sodium chloride (50 mM) was prepared and 200 µl of solution were added per well of a nickel-coated microtitre plate, followed by incubation at room temperature for a period of two hours. The microtitre plate
30 was then washed 5 times with the buffer solution and then incubated at 37°C for

one hour with a solution of bovine serum albumin (3% w/v) in the above buffer. After washing 5 times with phosphate buffered saline (PBS) with "Tween" 20 (polyoxyethylene (20) sorbitan monolaurate, 0.5% v/v), the GST-AsiA fusion protein prepared as described in *Example 4.1.* above (100 ng) was added together with a defined amount of a putative inhibitor of truncated sigma⁷⁰ protein (corallopyronin, myxopyronin or ripostatin) and incubated at 37°C for one hour. Further washing (5 times) with PBS-"Tween" 20 was carried out and then anti-GST antibodies (1:2000) raised in rabbits were added to the wells, with incubation at 37°C for one hour. The previous washing step was repeated and thereafter anti-rabbit IgG-horse radish peroxidase (HRP) conjugate (1:2000) was added and incubated at 37°C for one hour. A final wash with PBS-"Tween" 20 was carried out, before adding the HRP enzyme substrate, tetramethyl benzidine/ H₂O₂. The enzymic reaction (resulting in the development of colour) was stopped after a suitable period of time by the addition of 6N H₂SO₄ and the microtitre plate was "read" in a spectrophotometer using light of wavelength (λ) 450 nm. The results obtained are shown in Table 2 following.

TABLE 2

Test	% Binding to truncated sigma ⁷⁰
GST-AsiA (500 ng/ml)	100
GST-AsiA + AsiA (7 μ g/ml)	12
GST-AsiA + corallopyronin (30 μ g/ml)	69
GST-AsiA + myxopyronin (30 μ g/ml)	56
GST-AsiA + ripostatin (1 μ g/ml)	100
GST-AsiA + ripostatin (10 μ g/ml)	55
GST-AsiA + ripostatin (100 μ g/ml)	1.5

CLAIMS

1. A method of identifying a ligand of a bacterial sigma⁷⁰ subunit which comprises contacting the sigma⁷⁰ subunit or a portion thereof comprising the anti-sigma binding region, with a test compound and a fusion protein of an anti-sigma⁷⁰ factor of bacteriophage T₄, and determining whether the test compound binds competitively with the anti-sigma⁷⁰ factor to the sigma⁷⁰ subunit or portion thereof.
2. A method according to claim 1, which comprises:
 - (i) immobilizing the sigma⁷⁰ subunit or portion thereof on a matrix or solid support;
 - (ii) adding the test compound and the fusion protein;
 - (iii) adding a first antibody against the fusion protein;
 - (iv) adding a labeled second antibody against the first antibody; and
 - (v) determining the amount of second antibody bound to the (first antibody - fusion protein - sigma⁷⁰ subunit or portion thereof) complex formed on the matrix or solid support.
3. A method according to claim 1 or claim 2, wherein the sigma⁷⁰ subunit or portion thereof is obtained from *Escherichia coli* or *Salmonella typhimurium*.
4. A method according to any one of the preceding claims, wherein the anti-sigma⁷⁰ factor has an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2.
5. A method according to any one of the preceding claims, wherein the fusion protein also comprises glutathione-S-transferase.

6. A method according to any one of the preceding claims wherein the ligand is an inhibitor of a bacterial sigma⁷⁰ subunit.




Fig. 1





Fig. 2

*Fig. 3*




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. B

SEQUENCE LISTING

<110> ASTRA AKTIEBOLAG

<120> RNA Polymerase Assay

<130> R 1765

<140>

<141>

<160> 8

<170> PatentIn Ver. 2.0

<210> 1

<211> 90

<212> PRT

<213> Bacteriophage T4

<400> 1

Met Asn Lys Asn Ile Asp Thr Val Arg Glu Ile Ile Thr Val Ala Ser
1 5 10 15

Ile Leu Ile Lys Phe Ser Arg Glu Asp Ile Val Glu Asn Arg Ala Asn
20 25 30

Phe Ile Ala Phe Leu Asn Glu Ile Gly Val Thr His Glu Gly Arg Lys
35 40 45

Leu Asn Gln Asn Ser Phe Arg Lys Ile Val Ser Glu Leu Thr Gln Glu
50 55 60

Asp Lys Lys Thr Leu Ile Asp Glu Phe Asn Glu Gly Phe Glu Gly Val
65 70 75 80

Tyr Arg Tyr Leu Glu Met Tyr Thr Asn Lys
85 90

<210> 2

<211> 90

<212> PRT

<213> Bacteriophage T4

<400> 2

Met Gly Lys Asn Ile Asp Thr Val Arg Glu Ile Ile Thr Val Ala Ser
1 5 10 15

Ile Leu Ile Lys Phe Ser Arg Glu Asp Ile Val Glu Asn Arg Ala Asn
 20 25 30

Phe Ile Ala Phe Leu Asn Glu Ile Gly Val Thr His Glu Gly Arg Lys
 35 40 45

Leu Asn Gln Asn Ser Phe Arg Lys Ile Val Ser Glu Leu Thr Gln Glu
 50 55 60

Asp Lys Lys Thr Leu Ile Asp Glu Phe Asn Glu Gly Phe Glu Gly Val
 65 70 75 80

Tyr Arg Tyr Leu Glu Met Tyr Thr Asn Lys
 85 90

<210> 3

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 3

atggaattca acccgcagtc acagctg

27

<210> 4

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 4

tgagtcgact taatcgtcga ggaagct

27

<210> 5

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 5

ggccatgggc aataaaaaca ttgat

25

<210> 6

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 6

ggggatcctt atttggtcgt atacat

26

<210> 7

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 7

gaaagatctc atatgtcccc tatactaggt

30

<210> 8

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 8

ctaagctttt atttggtcgt atacatctc

29

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/00979

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: G01N 33/569, C07K 14/35, C07K 14/01
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: G01N, C07K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9625170 A1 (RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK), 22 August 1996 (22.08.96) --	1-6
A	WO 9638478 A1 (ASTRA AKTIEBOLAG), 5 December 1996 (05.12.96), especially claim 10 --	1-6
A	Databas Medline, accession no. 93106978, Orsini G et al: "The asiA gene of bacteriophage T4 codes for the anti-sigma 70 protein"; & J Bacteriol 1993 Jan; 175(1):85-93 -- -----	1-6

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 Sept 1999

Date of mailing of the international search report

26 -10- 1999

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson/EÖ
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT
Information on patent family members

30/08/99

International application No.
PCT/SE 99/00979

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9625170	A1	22/08/96	AU	4759596 A	04/09/96
WO	9638478	A1	05/12/96	AU	706367 B	17/06/99
				AU	4550896 A	26/09/96
				AU	5018496 A	18/12/96
				CA	2171600 A	14/09/96
				CN	1201465 A	09/12/98
				EP	0832116 A	01/04/98
				GB	2298862 A,B	18/09/96
				GB	9603860 D	00/00/00
				IE	960132 A	18/09/96
				NZ	286081 A	22/09/97
				SE	9501976 D	00/00/00
				SE	9502596 D	00/00/00
				SE	9503246 D	00/00/00